Transenterix Inc at JPMorgan Healthcare Conference Transcript
Good morning. I'm Anthony Fernando. I'm the CEO of TransEnterix. And over the next 10, 15 minutes, I'd just like to tell you a little bit about our company, where we are and where we're going over the next few years. These are some forward-looking statements. At TransEnterix, we believe in digitizing the interface between the surgeon and the patient in a way to increase control, reduce surgical variability and improve patient outcome in a value-based health care setting in a relatively very cost-effective manner. And I'll explain this to you as we go along through this presentation.
So who are we? We have a robotic surgical platform called Senhance. It's the first and only digital laparoscopy platform. There's significant market opportunity in robotics. We are FDA cleared, CE approved and we also have the PMDA approval in Japan. So ramping up our clinical adoption globally right now, and we are also the first and extremely well positioned to bring augmented intelligence in surgical robotics and also machine vision in surgery.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
